193 related articles for article (PubMed ID: 24851051)
1. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
[TBL] [Abstract][Full Text] [Related]
2. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
3. Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.
Jameson K; Zhang Q; Zhao C; Ramey DR; Tershakovec AM; Gutkin SW; Marrett E
Curr Med Res Opin; 2014 Apr; 30(4):655-65. PubMed ID: 24495126
[TBL] [Abstract][Full Text] [Related]
4. LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy.
Ashton V; Zhang Q; Zhang NJ; Zhao C; Ramey DR; Neff D; Tershakovec AM; Marrett E
Clin Ther; 2014 May; 36(5):792-9. PubMed ID: 24768187
[TBL] [Abstract][Full Text] [Related]
5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
6. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and types of persistent dyslipidemia in patients treated with statins.
Reiner Ž; Tedeschi-Reiner E
Croat Med J; 2013 Aug; 54(4):339-45. PubMed ID: 23986274
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
Goodman SG; Langer A; Bastien NR; McPherson R; Francis GA; Genest JJ; Leiter LA;
Can J Cardiol; 2010 Nov; 26(9):e330-5. PubMed ID: 21076724
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
11. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin: pharmacological characteristics and lipid-lowering effects.
Poli A
Drugs; 2007; 67 Suppl 1():3-15. PubMed ID: 17910517
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
[TBL] [Abstract][Full Text] [Related]
14. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
16. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
17. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
[TBL] [Abstract][Full Text] [Related]
18. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
